Research
Hormonal
PGC-1α acts as a direct repressor of NF-κB transcriptional activity, specifically blocking the expression of proinflammatory cytokines like IL-6 and TNF-α.
Regular physical activity and metabolic health practices naturally increase PGC-1α, which physically binds to and inhibits NF-κB, thereby reducing the production of inflammatory cytokines like IL-6 and TNF-α.
GoodSupportsHIGH confidence
Mechanistically speaking, levels of proinflammatory cytokines are regulated by PGC-1α through its physical interaction with the p65 NF-κB subunit. Consequently, PGC-1α blocks NF-κB transcriptional activity toward its target genes, including those encoding proinflammatory cytokines.
Why this rating
Supported by multiple citations showing physical binding and functional repression in various cell types.
Source
PGC-1<i>α</i>, Inflammation, and Oxidative Stress: An Integrative View in Metabolism
Sergio Rius‐Pérez et al. · Oxidative Medicine and Cellular Longevity · 2020
DOI 10.1155/2020/1452696
narrative_reviewCited 614×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Low levels of PGC-1α exacerbate inflammatory responses and oxidative stress by downregulating mitochondrial antioxidant genes and promoting NF-κB activation, creating a vicious cycle of metabolic dysfunction.Good
- Upregulation of PGC-1α enhances mitochondrial antioxidant defense by increasing the expression of genes such as MnSOD, catalase, and peroxiredoxin, thereby protecting cells from oxidative damage.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →